Download | October 19, 2018

This market research report is available for purchase below. It provides an overview of the current biologic sterile injectable market dynamics as well as what our survey respondents—all outsourcing decision-makers—predict the market will look like in 2022. Key statistics include development-stage and marketed product volume, the proportion outsourced, and the number of CMOs required to complete the work. You can purchase a single-user license for individual use, a site-wide license giving access to the report for all employees within a single site/office location, or an enterprise-wide license giving access to all employees within your organization. You can also download a free preview file below.

Drug Developers

  • Contract manufacturer selection factors and satisfaction drivers; CMO perception, use, and preference statistics, including verbatim preference responses for 22 different CMOs
  • Life cycle management and life cycle extension strategies utilized by industry peers, in addition to biologic sterile injectable market growth factors
  • Annual biologic sterile injectable expenditure and the proportion of spend in-house vs outsourced and how those figures will change over the next five years

Contract Manufacturers

  • Familiarize your company with outsourcing drug innovators’ portfolio composition and outsourcing likelihood by biologic drug category and delivery device and whether these practices will evolve in the next five years
  • Understand outsourcing motivations and commercial CMO engagement timelines for secondary manufacturing
  • Gain insight into why a CMO may lose a bid, preferred provider use and difficulty levels in using a CMO who is not on a preferred provider list
  • Learn biologic drug product project volume and outsourcing proportion by company type and development-stage vs commercial scale in order to better target sales and marketing efforts

Learn more by downloading the free preview file, or by purchasing the full report below.